Klinische trajecten en pathofysiologische drijfveren van vroege mortaliteit bij homozygote familiaire hypercholesterolemie

Een uitgebreide onderzoeksanalyse
Evidence-based cardiovasculair onderzoek

Overzicht en definities

homozygote familiaire hypercholesterolemie (HoFH) vertegenwoordigt de meest catastrofale en fenotypisch extreme manifestatie van erfelijke lipidenstoornissen. Het is een ultrazeldzame genetische aandoening gekenmerkt door het bijna volledig onvermogen van de lever om lagedichtheids- lipoproteïne (LDL) deeltjes uit de systemische circulatie, wat resulteert in plasma cholesterol niveaus die vanaf de geboorte aanzienlijk zijn verhoogd.^[1]

Historisch gezien werd HoFH gedefinieerd door een klassieke klinische triade: onbehandeld LDL-cholesterol (LDL-C) concentraties van meer dan 500 mg/dL (13 mmol/L), de aanwezigheid van pathognomonisch cutaan en pees xanthemen verschijnend in het eerste decennium van het leven, en bewijs van heterozygoot familiair hypercholesterolemie bij beide biologische ouders.^[1]

Het wetenschappelijke begrip van de ziekte heeft de afgelopen decennia een aanzienlijke paradigmaverschuiving ondergaan. Genetisch onderzoek heeft een breder fenotypisch spectrum aan het licht gebracht dan voorheen werd erkend, wat klinische instanties zoals de Europese Aderverkalking Society (EAS) om de diagnostische drempelwaarden te verfijnen. De consensusverklaring van de EAS uit 2023 beveelt aan dat HoFH klinisch wordt vermoed bij elk individu met onbehandelde LDL-C-waarden boven 400 mg/dL (~10 mmol/L), aangezien veel patiënten met genetisch bevestigde biallelische mutaties zich presenteren met waarden onder de traditionele afkapwaarde van 500 mg/dL.^[5] Dit is met name relevant bij pediatrische populaties, waar de LDL-C-waarden lager kunnen zijn als gevolg van voeding of fysiologische groei, maar toch een extreem cardiovasculair risico vormen.^[6]

De genetische architectuur van HoFH wordt voornamelijk gekenmerkt door biallelische mutaties in het LDLR gen, dat codeert voor de LDL-receptor verantwoordelijk voor de hepatische opname van cholesterolrijke deeltjes.^[8] Deze biallelicaire toestanden kunnen echt homozygoot zijn—waarbij de erferving van dezelfde pathogene variante van beide ouders—of compound heterozygoot, waarbij twee verschillende mutaties in hetzelfde gen betrokken zijn.^[8] Naast LDLR worden zeldzamere vormen van HoFH veroorzaakt door pathogene varianten in de apolipoproteïne B (APOB) gen, dat het vermogen van het LDL-deeltje aantast om aan zijn receptor te binden, en "gain-of-function"-mutaties in het proproteineconvertase subtilisine/kexine type 9 (PCSK9) gen, dat de intracellulaire afbraak van de LDL-receptor versnelt.^[10] Daarnaast resulteert een autosomaal recessieve vorm van de ziekte (ARH) in biallelic loss-of-function varianten in het LDLRAP1-gen.^[8]

De prevalentie van HoFH werd traditioneel geschat op 1 op de 1.000.000 personen, maar hedendaagse epidemiologische gegevens en bevindingen uit registers suggereren een hogere frequentie van ongeveer 1 op de 160.000 tot 1 op de 300.000.^[1,6] In specifieke populaties met stichterseffecten, zoals Frans-Canadezen, Libanese christenen, Zuid-Afrikaanse Afrikaners en bepaalde Asjkenazisch-Joodse gemeenschappen, kan de prevalentie aanzienlijk hoger zijn.^[16]

Differentiële diagnose is van cruciaal belang. Sitosterolemie (fytosterolemie), veroorzaakt door biallelische varianten in de ABCG5/ABCG8-genen, presenteert zich met extreme verhogingen van LDL-C en vroege xanthomen, maar reageert opmerkelijk goed op dieetaanpassingen en ezetimib. Lysosomale zuur-lipasedeficiëntie (LAL-D) leidt ook tot ernstige hypercholesterolemie en premature atherosclerose maar wordt behandeld met enzymvervangende therapie. Cerebrotendineuze xanthomatose (CTX) kan zich manifesteren met xanthomen die vergelijkbaar zijn met HoFH, hoewel de cholesterolspiegels typisch normaal tot mild verhoogd zijn.^[1]

Mechanisme van extreem risico in de vroegste levensfase

Het extreme cardiovasculaire risico bij HoFH wordt gedreven door de onophoudelijke opeenhoping van cholesterol in de vaatwand, die al in utero begint. Het centrale concept bij het kwantificeren van dit risico is de “cumulatieve cholesterolbelasting”, gedefinieerd als de totale massa LDL-C waaraan de slagader intima is in de loop der tijd blootgesteld.^[19]

De cumulatieve last wordt uitgedrukt in mmol/l-jaar. Klinisch bewijs geeft aan dat het optreden van klinische atherosclerotische hart- en vaatziekten (ASCVD) in de algemene bevolking komt overeen met een cumulatieve drempelwaarde van ongeveer 125 mmol/L-jaar (~4.800 mg/dL-jaar).^[62,63], terwijl de drempel voor de eerste myocardinfarct is ongeveer 160 mmol/L-jaar (~6.000 mg/dL-jaar). Een normolipidemisch individu bereikt de last van 160 mmol/L-jaar typisch rond de leeftijd van 55 jaar. Daarentegen bereikt een onbehandelde HoFH-patiënt met een LDL-C van ~500 mg/dL (~13 mmol/L) ditzelfde drempelniveau op ongeveer 12-jarige leeftijd, wat verklaart waarom kinderen met de meest ernstige nul-receptormutaties vaak een myocard infarct ondergaan of plotselinge hartdood vóór de leeftijd van 10 jaar.^[19,63]

De vasculaire pathologie van pediatrische HoFH

De pathofysiologie van atherosclerose bij pediatrische HoFH omvat een snelle progressie van endotheelactivatie naar gevorderde tandplak vorming. Onder invloed van extreme hypercholesterolemie, LDL-deeltjes dringen door in de arteriële intima, waar ze worden geoxideerd en opgenomen door macrofagen vormen schuimcellen.^[24] In de algemene bevolking duurt dit proces tientallen jaren om zich te ontwikkelen van vetstrepen tot obstructieve plaques. Bij HoFH is de pure instroom van lipoproteïnen in de vaatwand zo hoog dat deze vetvlekken binnen de eerste levensjaren evolueren tot complexe, lipidenrijke en zeer inflammatoire plaques.^[19]

A distinguishing feature of HoFH-associated vascular disease is its anatomical predilection for the aortawortel and the coronary ostia.^[27] The cholesterol-rich nature of these laesies frequently results in supravalvular aortic stenosis (SVAS). Unlike the degenerative valvular verkalking seen in elderly populations, SVAS in HoFH is characterized by massive infiltration of the aortic wall and valve leaflets by xanthomatous tissue.^[20,21] Furthermore, plaque deposition at the coronary ostia can lead to sudden, total occlusion even in children who do not yet have diffuse kransslagaderziekte.^[27]

The Role of Secondary Risk Modifiers

In addition to the primary LDL-C elevation, many HoFH patients have significantly elevated levels of Lipoproteïne(a) [Lp(a)]. Lp(a) is an LDL-like particle with an added apolipoprotein(a) moiety, conferring pro-thrombotic and pro-inflammatory properties. Because Lp(a) is cleared primarily via the LDL receptor, its levels are frequently twice as high in HoFH patients compared to the general population.^[2] The presence of high Lp(a) acts as a risk multiplier, further accelerating atherosclerosis and increasing the likelihood of plaque rupture of trombose at a young age.^[11]

The development of cutaneous xanthomas before the age of 4 is associated with a markedly increased risk of childhood kransslagaderziekte and early mortality.^[20] These deposits are not merely cosmetic; they represent the systemic spillover of cholesterol that the vascular system can no longer contain.^[2]

Magnitude of Lipid Abnormalities

The magnitude of hypercholesterolemia in HoFH is unparalleled in clinical medicine. Untreated totaal cholesterol levels typically range from 460 to 1,160 mg/dL (12–30 mmol/L), with LDL-C levels consistently exceeding 400 mg/dL (10 mmol/L) in most genetically confirmed cases.^[4,5] In extreme cases, particularly in individuals with null-receptor mutations, LDL-C can reach levels above 1,000 mg/dL (26 mmol/L), and the blood may take on a visually distinct, opaque appearance due to the extreme concentration of lipoproteins.^[2]

Apolipoprotein B and Particle Metrics

Apolipoprotein B (ApoB) is the primary structural eiwit of all atherogenic lipoproteins, including VLDL, IDL, Lp(a), and LDL. Because there is exactly one ApoB molecule per particle, its measurement provides a direct count of the total number of atherogene deeltjes in the circulation.^[35] The normal reference range for ApoB in adults is below 130 mg/dL, with a US population median of approximately 93 mg/dL. In HoFH, ApoB levels are typically four to six times higher than this reference range.^[35]

The pathophysiology of ApoB in HoFH is defined by two factors: overproduction and severely impaired clearance. The absence of functional LDL receptors leads to a prolonged residence time for LDL particles in the blood—approximately 5–6 days compared to the normal 2.5 days.^[70] This extended circulation time results in the particles becoming increasingly modified. While Pattern B (small, dense LDL) is generally more atherogenic because it more easily penetrates the arterial wall, in HoFH, the overwhelming mass of even larger LDL particles drives constant flux into the sub-endothelial space.^[39]

Lipid Profile Comparison by Genotype

The severity of the lipid abnormality is intrinsically linked to the functional status of the LDL receptor. Patients are categorized as receptor-negative (less than 2% of normal LDLR activity) or receptor-defective (2% to 25% of normal activity).^[1,56]

Parameter	Receptor-Negative HoFH	Receptor-Defective HoFH	Reference Range
Untreated LDL-C	>600 mg/dL (>15.5 mmol/L)	300–500 mg/dL (7.8–12.9 mmol/L)	<130 mg/dL (<3.4 mmol/L)
Untreated ApoB	>400 mg/dL (~4–6× normal)	200–400 mg/dL (~2–4× normal)	<130 mg/dL
Untreated Lp(a)	Frequently markedly elevated	Elevated	<30 mg/dL
LDLR Activity	<2% of normal	2%–25% of normal	100% (normal)
Response to Statines	Minimal (~14% LDL-C reduction)	Moderate (~23% LDL-C reduction)	High (40–55% reduction)

Table 1. Lipid profile comparison by LDLR genotype. Source: [1,3,41,71]

A study of the CASCADE FH Register in the United States demonstrated that untreated LDL-C levels were significantly higher in patients enrolled as children (median 776 mg/dL, IQR 704–892) compared to those enrolled as adults (median 533 mg/dL, IQR 467–702; p=0.001).^[31] This discrepancy likely reflects a survival bias, where children with the most extreme elevations are diagnosed early because they develop visible symptoms—xanthomas or early cardiaque voorvallen—while those with milder elevations may go undiagnosed until adulthood.^[23]

The LDL-C:ApoB Ratio and Discordance

The LDL-C:ApoB ratio is a surrogate for LDL particle size and cholesterol content. A ratio below 1.2 (expressed as mg/dL:mg/dL) indicates a predominance of small, dense LDL particles, which are highly susceptible to oxidation and more readily trapped within arterial proteoglycans.^[38] In true HoFH, however, LDL-C and ApoB are typically both concordantly high, meaning that the extreme risk is driven primarily by the sheer volume of cholesterol mass and particle number rather than a shift in particle size alone.^[18]

Clinical Severity and Natural History (Untreated)

The natural history of untreated HoFH is characterized by rapid, progressive atherosclerosis and a starkly shortened lifespan. Without intervention, the average age of death has historically been reported as approximately 18 years, with some children succumbing to myocardial infarction as early as age 5.^[17,31]

The Evolution of Clinical Manifestations

The first clinical signs are usually dermatological. Cutaneous xanthomas often appear in the first year of life, presenting as soft, yellow nodular lesions at sites of friction, such as the elbows, knees, and buttocks.^[8] Tendon xanthomas involve the thickening of the Achilles tendon and the extensor tendons of the hands.^[8]

As the cholesterol burden increases, vascular and valvular manifestations emerge. Arcus lipoides corneae and xanthelasmas are frequently observed before age 10.^[15] By the second decade, most untreated patients have developed symptomatic coronary slagader disease and/or aortic root disease.^[2]

Historical Case Evidence

In 1889, G. Lehzen and K. Knauss described two sisters who are now recognized as likely the first documented cases of HoFH.^[28] The 11-year-old sister developed multiple yellow spots and lumps beginning at age 3. By age 11, she presented with “egg-like” tumors on her hands and massive xanthomas on her Achilles tendons. Clinical examination revealed a long blowing systolic murmur, and she died shortly after a surgery.^[28]

The autopsy findings documented:

• Aorta: Thickened with fat-containing tissue and sclerotic plaques.
• Aortaklep: Stenotic due to massive intima changes.
• Carotid Artery: The left carotid was nearly completely occluded.
• Coronary Arteries: Both showed multiple plaques, with the left being severely affected.^[28]

Registry-Based Observations on Natural History

Data from contemporary registries in non-high-income countries, where access to advanced therapies is limited, reflect this historical pattern. In a study of 751 HoFH patients across 38 countries, those in non-high-income regions experienced their first major adverse cardiovascular event a decade earlier than those in high-income countries (median age 24 vs. 35 years).^[47]

Clinical Feature	Typical Age of Onset (Untreated)	Pathological Significance
Cutaneous Xanthomas	<1 year	Marker of extreme systemic saturation
Corneal Arcus	<10 years	Early indicator of lipid spillover
Tendon Xanthomas	5–15 years	Cumulative tissue deposition
Aortawortel Stenose	5–20 years	Primary cause of non-ischemic cardiac death
Myocardial Infarction	5–30 years	Result of ostial or diffuse CAD
Sudden Cardiac Death	Variable; can occur in childhood	Fatal arrhythmia or total ostial occlusion

Table 2. Clinical progression of untreated HoFH. Source: [2,19,47]

Why Some Patients Survive Longer Than Others

Despite the severe nature of the disease, there is significant inter-individual variability in survival. Some patients succumb to hartstilstand in early childhood, while others, even with identical genetic mutations, may live into their 50s or 60s. This heterogeneity is driven by a complex interplay of residual receptor activity, genetic modifiers, and the timing of therapeutic intervention.^[1]

Residual LDLR Activity and Mutation Type

The most powerful predictor of clinical outcome is the residual activity of the LDL receptor. Receptor-negative individuals (null/null; <2% activity) exhibit the highest LDL-C levels, the poorest response to traditional medications, and the earliest onset of ASCVD.^[3,56] Receptor-defective patients (2%–25% activity) often have LDL-C levels approximately 18% lower than receptor-negative patients and respond more vigorously to pharmacological up-regulation of the receptor.^[41] This genetic dosing effect can delay the onset of cardiovascular events by a decade or more.^[6]

Beschermende genetische modificatoren

PCSK9 Loss-of-Function (LOF)

PCSK9 is a protein that binds to the LDL receptor and targets it for lysosomal degradation. Individuals who co-inherit a loss-of-function variant in PCSK9 have naturally lower circulating PCSK9 levels, leading to a higher density of LDL receptors on the hepatocyte surface.^[13] Population studies show that PCSK9 LOF variants are associated with approximately 28% lower LDL-C and up to 88% reduction in CHD risk.^[69] In the context of HoFH, a PCSK9 LOF variant can significantly counteract the effect of a pathogenic LDLR variant, resulting in a much milder clinical phenotype than would otherwise be expected.^[14]

ANGPTL3 Loss-of-Function

Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoproteïnelipase and endothelial lipase. LOF variants in ANGPTL3 lead to lower levels of LDL, VLDL, and HDL through mechanisms largely independent of the LDL receptor.^[9] Because this pathway does not rely on LDLR, it acts as a potent modifier even in receptor-negative HoFH patients.^[9]

APOB Truncations

Some patients carry hypobetalipoproteinemia variants in the APOB gene that lead to reduced production of LDL particles. If a patient with an LDLR mutation also carries one of these variants, the liver produces fewer atherogenic vehicles, limiting the maximum LDL-C level achievable.^[54]

Therapeutic Era and Intervention Thresholds

Before the 1980s, treatment was limited to low-fat diets and early bile acid sequestrants, which were largely ineffective.^[17] The introduction of statins, and later LDL apheresis, began to extend the life expectancy of HoFH patients into the late 20s and 30s.^[17]

The modern era, characterized by the availability of receptor-independent therapies, has fundamentally changed the prognosis. Lomitapide (an MTP inhibitor that reduces VLDL/LDL production) reduces LDL-C by approximately 50% independent of receptor genotype.^[55,72] Evinacumab (an ANGPTL3 inhibitor) reduces LDL-C by 43–53% even in null-receptor patients.^[32] The combination of these agents, if started in early childhood, allows many patients to keep their cumulative cholesterol burden below critical thresholds for much longer.^[19]

Longest-Lived HoFH Cases

While the historic life expectancy was under 20 years, contemporary literature now documents survivors living into their 50s, 60s, and beyond.

The 57-Year-Old Tokyo Case (Komuro et al., 1987)

One of the first longest-lived cases reported was a 57-year-old Japanese male described in 1987.^[64] This patient was homozygous for an internalization defect in the LDL receptor (a Class 4 mutation), meaning the receptors could bind LDL but could not pull it into the cell. His LDL-C was 461 mg/dL—lower than typical null-receptor patients—which allowed him to survive into his late 50s despite the absence of modern statins during much of his life.^[64]

The 59-Year-Old Czech Case (Novák et al., 2025)

A 2025 study reported on several atypical Czech HoFH patients, including a 59-year-old male compound heterozygote for the p.Phe114Ile and p.Gly592Glu LDLR variants.^[49] This patient was not diagnosed with HoFH until age 41. Although he eventually required a coronary artery bypass graft at age 57 and had significant carotid narrowing, his survival was exceptional given his genetic makeup. His specific compound heterozygous combination evidently conferred enough residual LDLR activity to prevent childhood mortality despite decades of extreme LDL-C elevation.^[49]

The 72-Year-Old Heterozygous FH Case (Johnson et al., 2018)

An instructive case involves a 72-year-old male with a pathogenic LDLR variant (p.Val827Ile) who maintained untreated LDL-C consistently around 487 mg/dL throughout his life.^[37] Despite this extreme elevation and lifelong lack of treatment, he had an Agatston calciumscore of 0 on multiple scans—implying a complete absence of coronary artery calcification. His survival was attributed to an exceptionally high HDL-C (~68 mg/dL) and a Pattern A LDL (large, buoyant particles), which are less prone to oxidation and arterial retention.^[37] Editorial note: This patient has been confirmed as heterozygous FH, not HoFH, based on the primary publication.^[37] The case is cited here as an extreme FH phenotype illustrating the protective role of HDL-C and LDL particle size.

Contemporary Pediatric Successes

Registry data now show that children diagnosed at age 2 and started on aggressive therapy—including liver transplantation or apheresis—are reaching adulthood with minimal atherosclerotic burden.^[23] Case reports document patients managed with weekly plasmapheresis and LDL apheresis from their teens into their 30s, maintaining a high quality of life and illustrating that mechanical clearance of cholesterol can effectively substitute for missing hepatic receptors.^[59]

Summary Diagnostic and Clinical Tables

Table 3: Refined Clinical and Genetic Criteria for HoFH Diagnosis

Category	Diagnostic Threshold / Feature	Rationale
Untreated LDL-C	>400 mg/dL (>10 mmol/L)	Proposed by 2023 EAS to capture broader spectrum
Treated LDL-C	>300 mg/dL (>8 mmol/L) on statin + ezetimibe	Historical threshold; used when baseline is unknown
Genetic Criteria	Bi-allelic variants (LDLR, APOB, PCSK9, LDLRAP1)	Gold standard for confirmation
Physical Findings	Xanthomas before age 10; Corneal Arcus	Pathognomonic for extreme cumulative burden
Family History	HeFH in both biological parents	Consistent with autosomal codominant pattern
Non-Genetic Mimics	Sitosterolaemia; LAL-D; CTX	Must be excluded to ensure appropriate therapy

Source: [1,5]

Table 4: Functional Classification of LDLR Mutations in HoFH

Class	Mechanism of Defect	Phenotypic Severity	Therapeutic Implication
Class 1	No detectable synthesis (Null)	Extreme (>600 mg/dL)	No response to Statins/PCSK9i
Class 2	Defective transport (ER to Golgi)	Severe	Minimal drug response
Class 3	Defective binding (ApoB to LDLR)	Variable	May respond to PCSK9i
Class 4	Defective internalization	Moderate to Severe	Some residual clearance possible
Class 5	Defective recycling	Gematigd	Often responds to drug up-regulation
Class 6	Defective membrane insertion	Variable	Depends on density of insertion

Source: [3]

Table 5: Pediatric vs. Adult HoFH — CASCADE FH Registry (Cuchel et al., 2023)

Metric	Children (n=16) Median (IQR)	Adults (n=51) Median (IQR)
Age at Diagnosis (years)	2.5 (1–6)	23 (13–34)
Untreated LDL-C (mg/dL)	776 (704–892)	533 (467–702)
ASCVD at Enrollment	43.8%	78.4%
Aortic Valve Stenosis at Enrollment	18.8%	25.5%
CABG (any)	12.5%	41.2%

Source: [31]

Evidence Quality and Uncertainty

The scientific community’s understanding of HoFH has evolved from descriptive case studies to comprehensive international registries, but several critical areas of uncertainty remain.

Limitations of Current Evidence

The rarity of HoFH makes large-scale, gerandomiseerde gecontroleerde onderzoeken (RCTs) extremely difficult. Much of the evidence for long-term survival and treatment efficacy is derived from retrospective registry data (such as CASCADE FH or the Worldwide HoFH Study) or open-label phase 2 and phase 3 trials.^[17] While registries provide invaluable real-world data, they are subject to selection bias—patients who are more severely affected or who have access to specialized care are more likely to be enrolled.^[1]

A significant area of uncertainty is the missing genetic cause in approximately 20–40% of patients with a clinical diagnosis of HoFH.^[7,66] This suggests that there are either unidentified FH genes or that a polygenic mechanism—the accumulation of many small-effect variants—can mimic the severity of monogenic HoFH. The clinical management of these mutation-negative patients remains a challenge.^[67,68]

Gaps in Pediatric Management

While current guidelines recommend universal lipid screening in children, the optimal age for initiating advanced therapies (such as evinacumab or lomitapide) in toddlers is still under investigation.^[1] The long-term safety of these agents in developing children is a concern, yet the risk of waiting for more data is the development of irreversible aortic root disease.^[27]

Furthermore, the threshold hypothesis of cumulative cholesterol burden (expressed in mmol/L-years) is an elegant model but has not been prospectively validated as a definitive point of no return.^[19] There is debate over whether lowering LDL-C can actually regress existing pediatric plaques or merely prevent the formation of new ones.^[25]

Future Directions

The future of HoFH research lies in gene therapy and base editing. Agents intended to directly alter the LDLR or PCSK9 genes in the liver—including in vivo CRISPR base editing—are currently in preclinical and early klinische onderzoeken.^[52,53] These one-and-done therapies could theoretically eliminate the need for lifelong infusions and daily pills, but the long-term genomic stability and safety of these approaches remain the primary uncertainties of the coming decade.^[52,53]

Conclusie

HoFH is a life-threatening emergency that manifests in the first years of life. The magnitude of the lipid abnormality is so great that it overcomes standard biological repair mechanisms, necessitating a multi-hit, receptor-independent therapeutic approach. Survival variability is driven by the specific nature of the genetic defect and the presence of protective modifiers, but the most important determinant of life or death remains the timing of diagnosis and the intensity of LDL-C lowering achieved in the first decade of life.^[1,19,31]

Referenties

1. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157. doi:10.1093/eurheartj/ehu274
2. Rahman A, Ahmed MU, Islam AK, Karim A, Sarker SA. A young male with familial hypercholesterolemia. J Saudi Heart Assoc. 2012;24(4):261-264. doi:10.1016/j.jsha.2012.06.264
3. Suryawanshi YN, Warbhe RA. Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments. Cureus. 2023;15(11):e49121. Published 2023 Nov 20. doi:10.7759/cureus.49121
4. Ziajka PE. Management of patients with homozygous familial hypercholesterolemia. Am J Manag Care. 2013;19(13 Suppl):.
5. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197
6. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2015;36(9):560-565. doi:10.1093/eurheartj/ehu058
7. Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018;72(6):662-680. doi:10.1016/j.jacc.2018.05.044
8. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004;25(1):49-68.
9. van den Bosch SE, Corpeleijn WE, Hutten BA, Wiegman A. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment. Genes (Basel). 2023;14(3):669. Published 2023 Mar 7. doi:10.3390/genes14030669
10. Zhao L, Gao Y, Liu G, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(6):585-590. doi:10.3760/cma.j.cn112148-20210715-00591
11. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; September 23, 2024.
12. Razman AZ, Chua YA, Mohd Kasim NA, et al. Genetic Spectrum of Familial Hypercholesterolaemia in the Malaysian Community: Identification of Pathogenic Gene Variants Using Targeted Next-Generation Sequencing. Int J Mol Sci. 2022;23(23):14971. Published 2022 Nov 29. doi:10.3390/ijms232314971
13. Saavedra YG, Dufour R, Davignon J, Baass A. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study. Arterioscler Thromb Vasc Biol. 2014;34(12):2700-2705. doi:10.1161/ATVBAHA.114.304406
14. Bayona A, Arrieta F, Rodríguez-Jiménez C, et al. Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report. Medicine (Baltimore). 2020;99(34):e21754. doi:10.1097/MD.0000000000021754
15. Gidding SS, Champagne MA, de Ferranti SD, et al. The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-2192. doi:10.1161/CIR.0000000000000297
16. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093. Published 2017 Dec 7. doi:10.1038/nrdp.2017.93
17. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124(20):2202-2207. doi:10.1161/CIRCULATIONAHA.111.042523
18. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1-S8. doi:10.1016/j.jacl.2011.04.003
19. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437. doi:10.1093/eurheartj/ehv157
20. Bélanger AM, Akioyamen LE, Ruel I, Hales L, Genest J. Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century. Eur Heart J. 2022;43(34):3227-3239. doi:10.1093/eurheartj/ehac339
21. Rocha VZ, Santos RD. Past, Present, and Future of Familial Hypercholesterolemia Management. Methodist Debakey Cardiovasc J. 2021;17(4):28-35. Published 2021 Sep 24. doi:10.14797/mdcvj.887
22. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197
23. Family Heart Foundation, “Family Heart Foundation study shows some children with HoFH miss out on decades of life-saving treatment,” EurekAlert!, 2022. [Press release; cited for registry context only.]
24. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood. Korean Circ J. 2010;40(1):1-9. doi:10.4070/kcj.2010.40.1.1
25. Tousoulis D, Kampoli AM, Papageorgiou N, et al. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des. 2011;17(37):4089-4110. doi:10.2174/138161211798764843
26. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437. doi:10.1093/eurheartj/ehv157
27. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197
28. Ballantyne CM, Gellis L, Tardif JC, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026;335(2):129-139. doi:10.1001/jama.2025.20620
29. Maldar SB, Pinto CJ. Homozygous familial hypercholesterolaemia in a patient presenting with hypertensive encephalopathy. BMJ Case Rep. 2022;15(10):e250265. Published 2022 Oct 31. doi:10.1136/bcr-2022-250265
30. Suresh Kumar G, Mathbout MF, Fahsah I, Ghafghazi S. Case of homozygous familial hypercholesterolaemia with premature coronary artery disease. BMJ Case Rep. 2021;14(5):e242114. Published 2021 May 19. doi:10.1136/bcr-2021-242114
31. Cuchel M, Lee PC, Hudgins LC, et al. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023;12(9):e029175. doi:10.1161/JAHA.122.029175
32. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711-720. doi:10.1056/NEJMoa2004215
33. Palacio CH, Harring TR, Nguyen NT, Goss JA, O’Mahony CA. Homozygous familial hypercholesterolemia: case series and review of the literature. Case Rep Transplant. 2011;2011:154908. doi:10.1155/2011/154908
34. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262-268. doi:10.1016/j.atherosclerosis.2012.02.019
35. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
36. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-2157. doi:10.1093/eurheartj/ehu274
37. Johnson KW, Dudley JT, Bobe JR. A 72-Year-Old Patient with Longstanding, Untreated Familial Hypercholesterolemia but no Coronary Artery Calcification: A Case Report. Cureus. 2018;10(4):e2452. Published 2018 Apr 9. doi:10.7759/cureus.2452
38. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37(25):1944-1958. doi:10.1093/eurheartj/ehw152
39. Pencina KM, Pencina MJ, Lawler PR, et al. Interplay of Atherogenic Particle Number and Particle Size and the Risk of Coronary Heart Disease. Clin Chem. 2023;69(1):48-55. doi:10.1093/clinchem/hvac172
40. Drouin-Chartier JP, Tremblay AJ, Bergeron J, Lamarche B, Couture P. The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2017;136(9):880-882. doi:10.1161/CIRCULATIONAHA.117.029435
41. Bertolini S, Cantafora A, Averna M, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol. 2000;20(9):E41-E52. doi:10.1161/01.atv.20.9.e41
42. Jayaram S, Meera S, Kadi S, Sreenivasa N. An Interesting Case of Familial Homozygous Hypercholesterolemia-A Brief Review. Indian J Clin Biochem. 2012;27(3):309-313. doi:10.1007/s12291-011-0165-8
43. Bensabbahia D, El Achiwi M, Atrassi M, Abkari A, Widad G. Homozygous Familial Hypercholesterolemia in a Seven-Year-Old: A Case Study Highlighting the Importance of Early Diagnosis. Cureus. 2025;17(6):e86219. Published 2025 Jun 17. doi:10.7759/cureus.86219
44. Mainieri F, Tagi VM, Chiarelli F. Recent Advances on Familial Hypercholesterolemia in Children and Adolescents. Biomedicines. 2022;10(5):1043. Published 2022 Apr 30. doi:10.3390/biomedicines10051043
45. Grundy SM, Stone NJ; Guideline Writing Committee for the 2018 Cholesterol Guidelines. 2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. Ann Intern Med. 2019;170(11):779-783. doi:10.7326/M19-0365
46. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093. Published 2017 Dec 7. doi:10.1038/nrdp.2017.93
47. Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728. doi:10.1016/S0140-6736(21)02001-8
48. Vladimirova-Kitova L, Kitov S, Ganev M, Chochkova-Bukova L. Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form – 5 Years Follow-Up. Front Cardiovasc Med. 2021;8:743341. Published 2021 Oct 8. doi:10.3389/fcvm.2021.743341
49. Zlatohlávek L, Becherová Beňová J, Foglarová T, Dudková T, Hubáček JA. Case Report: Beating the assumed prognosis: homozygous familial hypercholesterolemia with unexpected long survival. Front Cardiovasc Med. 2025;12:1643771. Published 2025 Oct 20. doi:10.3389/fcvm.2025.1643771
50. Guo Q, Feng X, Zhou Y. PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis. Front Genet. 2020;11:1020. Published 2020 Sep 23. doi:10.3389/fgene.2020.01020
51. Bayona A, Arrieta F, Rodríguez-Jiménez C, et al. Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report. Medicine (Baltimore). 2020;99(34):e21754. doi:10.1097/MD.0000000000021754
52. Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429-434. doi:10.1038/s41586-021-03534-y
53. Lee RG, Mazzola AM, Braun MC, et al. Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models. Circulation. 2023;147(3):242-253. doi:10.1161/CIRCULATIONAHA.122.062132
54. Lacaze P, Riaz M, Sebra R, et al. Protective lipid-lowering variants in healthy older individuals without coronary heart disease. Open Heart. 2021;8(2):e001710. doi:10.1136/openhrt-2021-001710
55. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-46. doi:10.1016/S0140-6736(12)61731-0
56. Norata GD, Tibolla G, Catapano AL. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Vascul Pharmacol. 2014;62(2):103-111. doi:10.1016/j.vph.2014.05.011
57. Bytyçi I, Henein MY, Bytyqi S, et al. PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials. Drugs. 2026;86(2):231-242. doi:10.1007/s40265-025-02272-z
58. Banerjee P, Chan KC, Tarabocchia M, et al. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arterioscler Thromb Vasc Biol. 2019;39(11):2248-2260. doi:10.1161/ATVBAHA.119.313051
59. Alicezah MK, Razali R, Rahman T, et al. Homozygous familial hypercholesterolemia. Malays J Pathol. 2014;36(2):131-137.
60. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb. 2023;30(5):531-557. doi:10.5551/jat.CR006
61. Bélanger AM, Akioyamen L, Alothman L, Genest J. Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. Curr Opin Lipidol. 2020;31(4):176-181. doi:10.1097/MOL.0000000000000686
62. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/j.jacc.2018.06.046
63. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273
64. Komuro I, Kato H, Nakagawa T, et al. The longest-lived patient with homozygous familial hypercholesterolemia secondary to a defect in internalization of the LDL receptor. Am J Med Sci. 1987;294(5):341-345. doi:10.1097/00000441-198711000-00008
65. Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol. 2020;75(20):2553-2566. doi:10.1016/j.jacc.2020.03.057
66. Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139. doi:10.1016/j.jlr.2021.100139
67. Vrablik M, Tichý L, Freiberger T, Blaha V, Satny M, Hubacek JA. Genetics of Familial Hypercholesterolemia: New Insights. Front Genet. 2020;11:574474. Published 2020 Oct 7. doi:10.3389/fgene.2020.574474
68. Di Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: A complex genetic disease with variable phenotypes. Eur J Med Genet. 2020;63(4):103831. doi:10.1016/j.ejmg.2019.103831
69. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-1272. doi:10.1056/NEJMoa054013
70. Bilheimer DW, Stone NJ, Grundy SM. Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo. J Clin Invest. 1979;64(2):524-533. doi:10.1172/JCI109490
71. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36. doi:10.1016/S0140-6736(12)60771-5
72. Blom DJ, Averna MR, Meagher EA, et al. Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2017;136(3):332-335. doi:10.1161/CIRCULATIONAHA.117.028208